Aprocitentan: A New Frontier in Hypertension Management
International Journal of Pharmaceutical Science Invention · 2024
DOI: 10.35629/6718-13060810 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Pharmaceutical Science Invention, 2024. Verfasst von Rutuja.S.Dagale Rutuja.S.Dagale und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Aprocitentant is a novel antagonist of the neurokinin-1 (NK1) receptor, primarily developed for the treatment of chemotherapy-induced nausea and vomiting (CINV). This review provides a comprehensive analysis of its pharmacokinetics, clinical trial outcomes, and overall efficacy. Through a critical evaluation of existing studies, we assess its therapeutic potential, side effects, and overall significance in improving patient quality of life.
Zitieren
APA
Rutuja.S.Dagale, R., Sneha.B.Sable, S., bhangare, M. S. B. M. S., & Phalke, D. P. P. D. P. (2024). Aprocitentan: A New Frontier in Hypertension Management. International Journal of Pharmaceutical Science Invention. https://doi.org/10.35629/6718-13060810
Vancouver
Rutuja.S.Dagale R, Sneha.B.Sable S, bhangare MSBMS, Phalke DPPDP. Aprocitentan: A New Frontier in Hypertension Management. International Journal of Pharmaceutical Science Invention. 2024. doi:10.35629/6718-13060810
BibTeX
@article{RutujaSDagale2024,
author = {Rutuja.S.Dagale, Rutuja.S.Dagale and Sneha.B.Sable, Sneha.B.Sable and bhangare, Miss Sonali bhangare Miss Sonali and Phalke, Dr. Pallavi Phalke Dr. Pallavi},
title = {Aprocitentan: A New Frontier in Hypertension Management},
journal = {International Journal of Pharmaceutical Science Invention},
year = {2024},
doi = {10.35629/6718-13060810}
}
EUVIMED